ReviewVirulence2013
New antibiotic agents in the pipeline and how they can help overcome microbial resistance.
Review in Virulence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed.
- A Korean native halophyte extract attenuates the virulence of methicillin-resistant Staphylococcus aureus by inhibiting biofilm formation.Scientific reports · 2026Article
- Article
- Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Proteomic and metabolomic responses of priority bacterial pathogens to subinhibitory concentration of antibiotics.npj antimicrobials and resistance · 2025Article
- The association between antibiotic use in hospitals and residual antibiotic concentrations in hospital effluents: a pilot study.JAC-antimicrobial resistance · 2025Article
- The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier.Journal of xenobiotics · 2025Review
- Reviewing the Therapeutic Potential of Plant-based Natural Products against Multidrug-resistant Bacteria (MDR).Current drug research reviews · 2025Review
- Effects of cecropin antimicrobial peptides on growth and intestinal health in growing male minks.Frontiers in veterinary science · 2025Article
- Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.Kona : powder science and technology in Japan · 2025Article
- Assessing antibiotics consumption, use and outcomes in a Yemeni tertiary hospital: A prospective cross-sectional study.PloS one · 2025Article
- Innovative Therapeutic Strategies for Asthma: The Role of Gut Microbiome in Airway Immunity.Journal of asthma and allergy · 2025Review
- PA-Win2: In Silico-Based Discovery of a Novel Peptide with Dual Antibacterial and Anti-Biofilm Activity.Antibiotics (Basel, Switzerland) · 2024Article
- The Potential of Phage Treatment to Inactivate Planktonic and Biofilm-FormingMicroorganisms · 2024Article
- TEMPRO: nanobody melting temperature estimation model using protein embeddings.Scientific reports · 2024Article
- Design, synthesis and antibacterial activity evaluation of ebselen derivatives in NDM-1 producing bacteria.RSC medicinal chemistry · 2024Article
- Comparative study on Antibacterial efficacy of a series of chromone sulfonamide derivatives against drug-resistant and MDR-isolates.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Antimicrobial potential of Streptomyces coeruleofuscus SCJ isolated from microbiologically unexplored garden soil in Northwest Morocco.Scientific reports · 2024Article
- The Identification of a Novel Spider Toxin Peptide, Lycotoxin-Pa2a, with Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2023Article
- Article
- Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial resistance is a growing threat and yet few new antibiotics active against multi-resistant bacteria are being explored. A combination of falling profits, regulatory mechanisms and irrational and injudicious use of antibiotics has led to an alarming situation where some infections have no cure. In this article, we summarize the new developments that have been suggested to incentivize the pharmaceutical industries toward the field of infections. We also briefly mention the new compounds on the horizon and some newly approved compounds that might help us tide over this crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.